Comorbidities in ADHD children treated with methylphenidate: a database study.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Kraut, Angela ALangner, Ingo
Lindemann, Christina
Banaschewski, Tobias
Petermann, Ulrike
Petermann, Franz
Mikolajczyk, Rafael
Garbe, Edeltraut
Issue Date
2013
Metadata
Show full item recordAbstract
Methylphenidate (MPH) is the most common drug treatment of attention deficit / hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in the presence of certain psychiatric, cerebro- and cardiovascular conditions. We assessed MPH treatment prevalence and incidence and the frequency of comorbid conditions related to these contraindications in new MPH users compared to a control group without ADHD and ADHD medication.Citation
Comorbidities in ADHD children treated with methylphenidate: a database study. 2013, 13:11 BMC PsychiatryAffiliation
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.Journal
BMC psychiatryPubMed ID
23294623Type
ArticleLanguage
enISSN
1471-244Xae974a485f413a2113503eed53cd6c53
10.1186/1471-244X-13-11
Scopus Count
Collections
The following license files are associated with this item: